The Effect of Tolvaptan on Metabolism and Electrolyte Homeostasis in Patients with Heart Failure: A Systematic Review and Meta-Analysis.

IF 1.9 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Reviews in cardiovascular medicine Pub Date : 2024-09-19 eCollection Date: 2024-09-01 DOI:10.31083/j.rcm2509334

Yao Xiao, Yue Chen, Xianghao Zuo, Kadireya Mutalifu, Xiaoping Chen, Kai Liu

{"title":"The Effect of Tolvaptan on Metabolism and Electrolyte Homeostasis in Patients with Heart Failure: A Systematic Review and Meta-Analysis.","authors":"Yao Xiao, Yue Chen, Xianghao Zuo, Kadireya Mutalifu, Xiaoping Chen, Kai Liu","doi":"10.31083/j.rcm2509334","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to investigate the effect of tolvaptan on metabolism and electrolyte homeostasis in patients with heart failure (HF).Methods: Literature databases, such as PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, VIP, and WanFang Data, were systematically searched for relevant trials from inception to November 4, 2023. We used the fixed effect model to combine the effect sizes and used I2 to test heterogeneity. Funnel plots were plotted to assess publication bias.Results: 16 studies were eligible for further analysis. No significant differences were identified in the incidence of hyperuricemia between the tolvaptan group and the placebo group (odds ratio (OR) = 1.23, 95% confidence interval (CI) = 0.97 to 1.55, p = 0.09). Tolvaptan decreased the levels of blood uric acid compared to traditional diuretics (mean difference (MD) = -82.8, 95% CI = -96.48 to -69.13, p < 0.00001). There was no significant difference in hypernatremia (OR = 1.62, 95% CI = 0.66 to 3.96, p = 0.29) and hyperkalemia (OR = 1.17, 95% CI = 0.93 to 1.48, p = 0.18) between the tolvaptan and control groups.Conclusions: Tolvaptan reduced the level of blood uric acid compared to conventional diuretics, and could be used as a substitute for traditional diuretics for HF patients with a high risk of gout.","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"25 9","pages":"334"},"PeriodicalIF":1.9000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440402/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in cardiovascular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/j.rcm2509334","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to investigate the effect of tolvaptan on metabolism and electrolyte homeostasis in patients with heart failure (HF).

Methods: Literature databases, such as PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, VIP, and WanFang Data, were systematically searched for relevant trials from inception to November 4, 2023. We used the fixed effect model to combine the effect sizes and used I² to test heterogeneity. Funnel plots were plotted to assess publication bias.

Results: 16 studies were eligible for further analysis. No significant differences were identified in the incidence of hyperuricemia between the tolvaptan group and the placebo group (odds ratio (OR) = 1.23, 95% confidence interval (CI) = 0.97 to 1.55, p = 0.09). Tolvaptan decreased the levels of blood uric acid compared to traditional diuretics (mean difference (MD) = -82.8, 95% CI = -96.48 to -69.13, p < 0.00001). There was no significant difference in hypernatremia (OR = 1.62, 95% CI = 0.66 to 3.96, p = 0.29) and hyperkalemia (OR = 1.17, 95% CI = 0.93 to 1.48, p = 0.18) between the tolvaptan and control groups.

Conclusions: Tolvaptan reduced the level of blood uric acid compared to conventional diuretics, and could be used as a substitute for traditional diuretics for HF patients with a high risk of gout.

查看原文本刊更多论文

托伐普坦对心力衰竭患者代谢和电解质平衡的影响：系统综述与元分析》。

研究背景本研究旨在探讨托伐普坦对心力衰竭（HF）患者代谢和电解质平衡的影响：在PubMed、EMBASE、Cochrane图书馆、中国知网、VIP和万方数据等文献数据库中系统检索了从开始到2023年11月4日的相关试验。我们使用固定效应模型合并效应大小，并使用 I2 检验异质性。绘制漏斗图以评估发表偏倚：16项研究符合进一步分析的条件。托伐普坦组与安慰剂组的高尿酸血症发生率无明显差异（几率比（OR）= 1.23，95% 置信区间（CI）= 0.97 至 1.55，P = 0.09）。与传统利尿剂相比，托伐普坦能降低血尿酸水平（平均差 (MD) = -82.8，95% 置信区间 (CI) = -96.48 至 -69.13，p < 0.00001）。托伐普坦组和对照组在高钠血症（OR = 1.62，95% CI = 0.66 至 3.96，p = 0.29）和高钾血症（OR = 1.17，95% CI = 0.93 至 1.48，p = 0.18）方面没有明显差异：与传统利尿剂相比，托伐普坦能降低血尿酸水平，可作为痛风高风险高频患者传统利尿剂的替代品。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reviews in cardiovascular medicine 医学-心血管系统

CiteScore

2.70

自引率

3.70%

发文量

377

审稿时长

1 months

期刊介绍： RCM is an international, peer-reviewed, open access journal. RCM publishes research articles, review papers and short communications on cardiovascular medicine as well as research on cardiovascular disease. We aim to provide a forum for publishing papers which explore the pathogenesis and promote the progression of cardiac and vascular diseases. We also seek to establish an interdisciplinary platform, focusing on translational issues, to facilitate the advancement of research, clinical treatment and diagnostic procedures. Heart surgery, cardiovascular imaging, risk factors and various clinical cardiac & vascular research will be considered.